Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung CancerReport as inadecuate




Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer - Download this document for free, or read online. Document in PDF available to download.

Background: Efficacy and safety data for cisplatin and pemetrexed plusbevacizumabinnon squamousnon non-small cell lung cancer NSCLC are stilllimited. Nevertheless, either bevacizumab plus platinum doublet or pemetrexedplus platinum is approved options for first line therapy. Predictive factorsfor bevacizumab are needed. KRAS isone of the most common oncogenic drivers in lung cancer. Its prognostic andpredictive value in NSCLC is under investigation. Patients and methods: Thistrial evaluates the addition of bevacizumab 7.5 mg-kg to cisplatin 75 mg-m2 plus pemetrexed 500 mg-m2 as first line treatment in stage IVnon-squamous NSCLC patients. Maintenance bevacizumab was received asmonotherapy until progressive disease, unacceptable toxicityor consent with drawal.The primary objective was progression free survival PFS. Secondary objectivesincluded overall survival OS, safety, global objective responses and thedetermination of KRAS mutation atbaseline. Results: From March 2009 to March2012, 31 patients were enrolled. Mean age was 59.19standard deviation SD 8.53. From all the patients included in this trial,67.70% were men. KRAS was wild type in 19 patients 58.06%; in 722.58% was mutated and was unknown in 6 patients 19.35%. Median OS was shorter than the reported in previous trials withbevacizumab. Nevertheless, focussing on the OS for KRAS wild type patients, this achieves a result or 16.1 months.Therefore, this would be a consistent data supporting to qualify this parameteras a predictive factor before starting treatment for NSCLC.

KEYWORDS

Non-Small-Cell Lung Cancer, Bevacizumab, Pemetrexed, Predictive Biomarker, KRAS

Cite this paper

Vivanco, G. , Azkona, E. , Carrera, S. , Sancho, A. , Rubio, I. , Mañé, J. , Calvo, B. , Aresti, U. , Buque, A. , Marrodán, I. and Muñoz, A. 2016 Final Results of a Phase II Study of Bevacizumab, Cisplatin and Pemetrexed as First-Line Therapy for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer. Journal of Cancer Therapy, 7, 455-463. doi: 10.4236-jct.2016.77047.





Author: Guillermo López Vivanco*, Eider Azkona, Sergio Carrera, Aintzane Sancho, Itziar Rubio, Juan Manuel Mañé, Begoña Calvo, Unai A

Source: http://www.scirp.org/



DOWNLOAD PDF




Related documents